Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Stevanato Group to Present at the Bank of America Securities Healthcare Conference


Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024.

The Company will present on Wednesday, May 15, 2024 at 11:20 a.m. (PT). A live webcast will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. A replay of the webcast will be available for approximately 90 days after the event.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.

For more information, please visit www.stevanatogroup.com.


These press releases may also interest you

at 21:03
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

at 21:00
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...

at 20:54
Starlight Children's Foundation CEO, Adam Garone, Named Nonprofit Executive of the Year by Los Angeles Business Journal
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...

at 20:35
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2...

at 19:56
Rare Cannabinoid Company Launches Dispensary-Strength CBG + CBD + THC Rapid Relief Gel With Free Sample Offer
Rare Cannabinoid Company is proud to announce the launch of its new,...

at 18:58
Children's Health and UT Southwestern Receive $100 Million Donation from the Pogue Family for New $5 Billion Dallas Pediatric Campus
Children's HealthSM and UT Southwestern Medical Center announced a historic gift of $100 million from the Jean and Mack Pogue family in support of the $5 billion new Dallas pediatric campus, unveiled earlier this year. The gift from the Pogue...

More news about Health...


News published on and distributed by: